pharmaphorum Daily Newsletter - 17th Dec.
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
This Tuesday, we learn that ‘exciting’ Phase 2b results with Sanofi and Teva's duvakitug warrant a swift move to phase 3 in inflammatory bowel disease.
In other news today, Closed Loop Medicine 's smartphone app for blood pressure monitoring has shown proof-of-concept in the Cure-19 study, whereas elsewhere MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.
Meanwhile, the FDA has sent a complete response letter to Johnson & Johnson, denying approval of its subcutaneous version of lung cancer therapy Rybrevant, and legislation that would introduce big changes for pharmacy benefit managers is inching closer to realisation in the US Congress.
All this and more on pharmaphorum.com
News
Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.
Closed Loop Medicine's smartphone app for blood pressure monitoring has shown proof-of-concept in the Cure-19 study.
MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.
FDA has sent a complete response letter to J&J, denying approval of its subcutaneous version of lung cancer therapy Rybrevant.
Legislation that would introduce big changes for pharmacy benefit managers (PBMs) is inching closer to realisation in the US Congress.
Views & Analysis
In a new report, ‘Helping others: unlocking the potential of ‘other’ cancers through predictive analytics’, the Concr team looked at how ‘common’ cancers like lung, breast, prostate, pancreas, and colorectal cancers ‘dominate’ not just clinical trials, but also data collection efforts more generally.
Recruiting for clinical trials is hard… and expensive. And a large component of that time involves people sifting through medical data, by hand, to see if someone qualifies for a study or not.
Discover how the integration of ECG data and AI is transforming the pharmaceutical industry, revolutionising drug development and commercialisation.
Incorporating environmentally friendly practices has become everyone's responsibility. In recent years, policymakers and organisations have particularly intensified sustainability practices among pharma and biotech.
Timely patient access to medication has become an acute problem in the UK healthcare system, with patients often caught in a tug-of-war between an overburdened NHS and the high costs of traditional healthcare.
领英推荐
Podcasts & Videos
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio , a company focused on the small molecule space, with its team of scientists, entrepreneurs, drug creators, and problem solvers working together to bring new medicines to patients who currently have few options.
In a pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Sharmeen Roy, chief scientist at DoseMe , for a conversation on precision medicine tools and how pharmacokinetic (or PK) and pharmacodynamic (or PD) characteristics are a – long overdue – trend in pharma at the moment, from lead identification right up to final-stage clinical trials.
In this pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius BioTherapeutics , a company working in the in vivo cell therapy space.
Clinical research is full of challenges, from recruitment to data management to global resourcing. Working with a functional service provider (FSP) can be a great option for meeting these needs. But what exactly is an FSP, and what are the advantages to working with one? In this interview, brought to you by Advanced Clinical, Programme Directors Lori Fletcher and Amber Beimer speak with pharmaphorum editor-in-chief Jonah Comstock and clear up some misconceptions that FSPs are merely staffing agencies.
In today’s podcast, web editor Nicole Raleigh is joined by Jesse Mendelsohn, senior vice president of Model N’s Center of Excellence, for a conversation that explores multiple aspects of the drug pricing debate in America – speaking before President-Elect Donald Trump confirmed his nomination of Robert F Kennedy Jr as US Health and Human Services Secretary.
White Papers & Webinars
A panel of experts, including from IPG Health, have shared their sector experience and wisdom in a new 60 Seconds white paper, ‘Moments of Truth: Launch’, to highlight the need to create and champion an organisational culture that underwrites a new product’s potential.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health , entitled ‘Health Trends 2025: Reimagining What's Possible’. This forward-looking session will explore how imagination and innovation are reshaping the future of healthcare.
An exclusive webinar, sponsored by Trueblue , explores how life sciences organisations are leveraging the power of AI-driven strategic insights to revolutionise decision-making, enhance customer engagement, and gain a competitive edge. Available now on demand.
In this webinar, sponsored by PurpleLab , learn how to gain a competitive edge by understanding physician prescribing behaviour in target markets. Available now on demand.
In a webinar sponsored by Syneos Health - with Atlas Clinical Research ’s Chief Executive Officer Mark Scullion, and Batisha Anson, Global Head of Patient Diversity and Health Equity at Syneos Health - learn more about the site experience for clinical research sites. Now available on demand.